TABLE 4

In vivo concentrations of the inducers at different dose regimens.


Inducer

Dose Regimen

Cmax, ss

Reference
μM
BST 125 mg b.i.d. 5 days 2.0 Dingemanse et al., 2003
BST 500 mg b.i.d. 7 days 14.4 Binet et al., 2000
DEX 8 mg, b.i.d., 5 days 0.1 McCune et al., 2000
CMZ 50 mg b.i.d. 2 wk 8.0 Yasui-Furukori et al., 2003
CMZ 100 mg t.i.d. 10 days 17.8 Furukori et al., 1998
CMZ 150 mg b.i.d. 2 wk 17.7 Yasui-Furukori et al., 2003
CMZ 200 mg b.i.d. 4 days or q.d. 5 days 13.5-22.8 Otani et al., 1996a; Masui et al., 2006
CMZ 300 mg b.i.d. 2 wk 25.0 Yasui-Furukori et al., 2003
CMZ 400 mg q.d. 4 wk 20.3-23.3 Otani et al., 1996b; Schlienger et al., 2000
CMZ 600 mg q.d. 9 wk 22.0-33.0 de Leon and Bork, 1997; Licht et al., 2000
CMZ 800 mg q.d. 7 days 31.3 Hillebrand et al., 1987
CMZ 942 mg 6 wk 39.8 Ketter et al., 1995
CMZ 1400-1650 mg (chronic) 40.8-41.7 May et al., 1996, 2003
EFA 200 or 400 mg q.d. 10 days 6.9 Mouly et al., 2002
EFA 600 mg q.d. 10 days 10.6-14.9 Veldkamp et al., 2001; la Porte et al., 2004b; Weiner et al., 2005
EFA 800 mg q.d. 7 days 11.31 Lopez-Cortes et al., 2002
PB 30 mg b.i.d. (chronic) 31.2-36.6 Back et al., 1980
PB 90 mg q.d. 29 days 56.8-66.3 Ferron et al., 2003
PB 100 mg q.d. 21 days 59.0-65.0 Kapil et al., 1987; Rutledge et al., 1988
PB 140 mg q.d. 19 days 123.6 Saccar et al., 1985
PB 200 mg q.d. 7 days 105.0 Williams et al., 1983
RIF 300 mg b.i.d. 13.5 days 4.1-8.9 Drusano et al., 1986;Chandler et al., 1990
RIF 600 mg q.d. 10 days 10.2-18.2 Boyd et al., 2003b; la Porte et al., 2004a; Stone et al., 2004; Droste et al., 2005
RIF
900 mg q.d. 10 days
12.1
Humbert et al., 1991